The US Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in ...
Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing ...
35m
BioArctic AB (BRCTF) reports significant licensing deals and growing market demand, while navigating regulatory challenges and increased expenses.
The Global Implantable Drug Delivery Devices Market was valued at USD 26.7 Bn in 2023. It is expected to reach USD 57.1 Bn by 2033, with a CAGR of 8.1% ...
The report "Medical Filtration Market by Material (Polyethersulfone; Polyvinylidenefluoride), Applications (Dialysis; Sterile ...
CSL Limited (OTC:CSLLY) and uniQure Inc (NASDAQ:QURE) announced the four-year results from the pivotal HOPE-B study ...
CSL Behring has shared positive four-year results from a late-stage study of its haemophilia B gene therapy Hemgenix ...
CSL Behring's gene therapy Hemgenix four years post-infusion data continue to show sustained efficacy and safety in adults with haemophilia B: King of Prussia, Pennsylvania Monday ...
18h
Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug ...
A hush settles over the global tech community whenever a new headline drops on the future of artificial intelligence. In the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback